Cocrystal Pharma, Inc. (COCP) News

Cocrystal Pharma, Inc. (COCP): $1.53

0.03 (+2.33%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

C

Add COCP to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#248 of 455

in industry

Filter COCP News Items

COCP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

COCP News Highlights

  • For COCP, its 30 day story count is now at 2.
  • Over the past 7 days, the trend for COCP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about COCP are CC, WASH and DEC.

Latest COCP News From Around the Web

Below are the latest news stories about COCRYSTAL PHARMA INC that investors may wish to consider to help them evaluate COCP as an investment opportunity.

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

BOTHELL, Wash., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the achievement of first-patient-in for the Phase 2a human challenge clinical trial with CC-42344, an investigational new oral antiviral inhibitor for the treatment of pandemic and seasonal influenza A. This randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, viral and clinical measurements of influenza A infection in subjects dos

Yahoo | December 6, 2023

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

BOTHELL, Wash., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces the presentation of favorable data demonstrating activity of its potent broad-spectrum PB2 inhibitor CC-42344 against pandemic and seasonal influenza A strains at the World Vaccine Congress West Coast. Cocrystal has initiated a Phase 2a human challenge trial with oral CC-42344 in the UK in subjects infected with influenza A, and plans to begin a Phase 1 trial with inh

Yahoo | November 29, 2023

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

BOTHELL, Wash., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that James Martin, Chief Financial Officer and Co-Chief Executive Officer, will present a Company overview at Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on Monday, December 4 at 1:30 p.m. Eastern time. The conference is being held December 3-5 at the College of Business Executive Education Building at Florida Atlantic University in Boca Raton,

Yahoo | November 27, 2023

COCP: Cocrystal Pharma reports 3rd quarter financial results and provides updates on clinical trials.

By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT No revenues were reported in the 3rd quarter of 2023 Cocrystal Pharma’s (NASDAQ:COCP) as the company’s drug candidates are still in development stage and milestone payments from Merck have not been received. Research and development expenses for the quarter increased to $4.2 million compared to $3.9 million in the 3rdquarter of

Yahoo | November 14, 2023

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviralDosing expected to begin later this year in Phase 2a human challenge trial with oral CC-42344 for the treatment of pandemic and seasonal influenza APhase 1 trial with inhaled CC-42344 expected to begin in the first half of 2024 BOTHELL, Wash., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial re

Yahoo | November 13, 2023

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces that President and co-CEO Sam Lee, PhD will discuss progress in developing the novel, broad-spectrum PB2 inhibitor CC-42344 in an oral presentation, “Taking a new route: Development of novel inhaled and oral influenza antiviral, CC-42344” at the World Vaccine Congress West Coast on Tuesday, November 28, 2023 at 3:20 p.m. Pacific Time. The conference is being held Nove

Yahoo | November 9, 2023

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

BOTHELL, Wash., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces receipt of authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a Phase 2a human challenge trial with its broad-spectrum, oral PB2 inhibitor CC-42344 as a potential treatment for pandemic and seasonal influenza A. Cocrystal expects to begin treating influenza-infected subjects in this trial during the fourth quarter o

Yahoo | October 31, 2023

COCP: Cocrystal Pharma doses 1st subjects in the important CDI-988 clinical trial.

By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT On September 23, 2023, Cocrystal Pharma (NASDAQ:COCP) announced the dosing of the first subjects in its Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease inhibitor CDI-988. This pan-viral protease inhibitor was discovered using the company’s proprietary structure-based drug

Yahoo | October 2, 2023

Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus

BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease inhibitor CDI-988. This pan-viral protease inhibitor was discovered using the Company’s proprietary structure-based drug discovery platform technology. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of or

Yahoo | September 28, 2023

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

BOTHELL, Wash., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing novel small molecule antiviral therapeutics, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Cocrystal presentation will be available on the IR Calendar section of the Company’s website beginning Monday

Yahoo | September 5, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!